Abstract

177Lu-PSMA is a new, promising treatment option in patients with metastatic castration-resistent prostate carcinoma (mCRPC). The radioactive-labeled medication is given intravenously in 1–6 cycles, in which the β‑radiation causes damage to the cellular DNA and eventually cell death of prostate cancer cells that express PSMA. In mostly retrospective studies, a decrease is seen in the serum-PSA level of ≥ 50% in 40–60% of patients that have been previously extensively treated. A survival benefit is observed, but mostly within non-randomized studies. The toxicity of treatment is relatively mild with grade I–II CTCAE xerostomia in 30–50% of patients and a passing grade III–IV CTCAE hematologic toxicity (thrombocytopenia, leukopenia) in 0–15%. The medication is under study in multiple prospective studies in patients with mCRPC and in one randomized clinical trial. The use of 177Lu-PSMA in patients with earlier phases of disease is explored. Until proven of benefit in RCTs, 177Lu-PSMA therapy remains experimental.
Translated title of the contribution177Lutetium PSMA radioligand therapy in prostate cancer
Original languageDutch
JournalTijdschrift voor Urologie
DOIs
Publication statusE-pub ahead of print - 14 Jan 2020

Cite this

@article{fe437685f1274d9bb6e2b43453e412da,
title = "177Lutetium PSMA-radioligandtherapie bij prostaatkanker",
abstract = "177Lu-PSMA is a new, promising treatment option in patients with metastatic castration-resistent prostate carcinoma (mCRPC). The radioactive-labeled medication is given intravenously in 1–6 cycles, in which the β‑radiation causes damage to the cellular DNA and eventually cell death of prostate cancer cells that express PSMA. In mostly retrospective studies, a decrease is seen in the serum-PSA level of ≥ 50{\%} in 40–60{\%} of patients that have been previously extensively treated. A survival benefit is observed, but mostly within non-randomized studies. The toxicity of treatment is relatively mild with grade I–II CTCAE xerostomia in 30–50{\%} of patients and a passing grade III–IV CTCAE hematologic toxicity (thrombocytopenia, leukopenia) in 0–15{\%}. The medication is under study in multiple prospective studies in patients with mCRPC and in one randomized clinical trial. The use of 177Lu-PSMA in patients with earlier phases of disease is explored. Until proven of benefit in RCTs, 177Lu-PSMA therapy remains experimental.",
keywords = "Lutetium, PSMA, imaging, metastases, prostate carcinoma",
author = "Vis, {Andr{\'e} N.} and Jansen, {Bernard H. E.} and Bodar, {Yves J. L.} and Nieuwenhuijzen, {Jakko A.} and Hendrikse, {Harry N.} and Oprea-Lager, {Daniela E.}",
year = "2020",
month = "1",
day = "14",
doi = "10.1007/s13629-019-00275-6",
language = "Dutch",
journal = "Tijdschrift voor Urologie",
issn = "2211-3037",
publisher = "Springer Science + Business Media",

}

TY - JOUR

T1 - 177Lutetium PSMA-radioligandtherapie bij prostaatkanker

AU - Vis, André N.

AU - Jansen, Bernard H. E.

AU - Bodar, Yves J. L.

AU - Nieuwenhuijzen, Jakko A.

AU - Hendrikse, Harry N.

AU - Oprea-Lager, Daniela E.

PY - 2020/1/14

Y1 - 2020/1/14

N2 - 177Lu-PSMA is a new, promising treatment option in patients with metastatic castration-resistent prostate carcinoma (mCRPC). The radioactive-labeled medication is given intravenously in 1–6 cycles, in which the β‑radiation causes damage to the cellular DNA and eventually cell death of prostate cancer cells that express PSMA. In mostly retrospective studies, a decrease is seen in the serum-PSA level of ≥ 50% in 40–60% of patients that have been previously extensively treated. A survival benefit is observed, but mostly within non-randomized studies. The toxicity of treatment is relatively mild with grade I–II CTCAE xerostomia in 30–50% of patients and a passing grade III–IV CTCAE hematologic toxicity (thrombocytopenia, leukopenia) in 0–15%. The medication is under study in multiple prospective studies in patients with mCRPC and in one randomized clinical trial. The use of 177Lu-PSMA in patients with earlier phases of disease is explored. Until proven of benefit in RCTs, 177Lu-PSMA therapy remains experimental.

AB - 177Lu-PSMA is a new, promising treatment option in patients with metastatic castration-resistent prostate carcinoma (mCRPC). The radioactive-labeled medication is given intravenously in 1–6 cycles, in which the β‑radiation causes damage to the cellular DNA and eventually cell death of prostate cancer cells that express PSMA. In mostly retrospective studies, a decrease is seen in the serum-PSA level of ≥ 50% in 40–60% of patients that have been previously extensively treated. A survival benefit is observed, but mostly within non-randomized studies. The toxicity of treatment is relatively mild with grade I–II CTCAE xerostomia in 30–50% of patients and a passing grade III–IV CTCAE hematologic toxicity (thrombocytopenia, leukopenia) in 0–15%. The medication is under study in multiple prospective studies in patients with mCRPC and in one randomized clinical trial. The use of 177Lu-PSMA in patients with earlier phases of disease is explored. Until proven of benefit in RCTs, 177Lu-PSMA therapy remains experimental.

KW - Lutetium

KW - PSMA

KW - imaging

KW - metastases

KW - prostate carcinoma

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85078253771&origin=inward

U2 - 10.1007/s13629-019-00275-6

DO - 10.1007/s13629-019-00275-6

M3 - Article

JO - Tijdschrift voor Urologie

JF - Tijdschrift voor Urologie

SN - 2211-3037

ER -